中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.02 seconds)

    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA
    1.
    发明申请
    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA 审中-公开
    微生物在MUCOSA的降低的结合

    公开(公告)号：US20110150850A1

    公开(公告)日：2011-06-23

    申请号：US12737929

    申请日：2009-09-29

    Applicant: Lothar Steidler

    Inventor： Lothar Steidler

    IPC: A61K35/74 ,  C12N1/00 ,  C12N1/20 ,  C12N1/16 ,  C12N1/14 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  A61K35/66 ,  A61P43/00

    CPC classification number: C12N1/36 ,  A61K47/6901 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/55594 ,  C12N9/1007 ,  C12P21/02 ,  C12Y201/01045

    Abstract: The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans.

    Abstract translation: 本发明涉及使用工程微生物来递送和给予患有疾病的人或动物的治疗性肽或蛋白质，或者使用工程微生物来递送抗原，例如用于疫苗接种目的。 更具体地，本发明涉及与其野生型祖先相比具有降低的粘膜能力的重组微生物，特别是当作为人或动物的治疗或疫苗接种的一部分驻留在消化道中时。 特别地，重组微生物含有无活性的胸苷酸合酶基因，其导致微生物在消化道中定居的能力降低。 本发明还涵盖了包含核酸或载体用于表达异源或同源蛋白质的所述重组微生物的用途; 并且还用于将所述蛋白质递送，特别是治疗性递送给动物或人。

    Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
    4.
    发明申请
    Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies 审中-公开
    用于鉴定药物靶标和增强癌症治疗的反义寡核苷酸

    公开(公告)号：US20060089322A1

    公开(公告)日：2006-04-27

    申请号：US10513255

    申请日：2003-05-01

    Applicant: Mark Vincent ,  Donald Koropatnick ,  Randall Berg

    Inventor： Mark Vincent ,  Donald Koropatnick ,  Randall Berg

    IPC: A61K48/00 ,  A61K31/7072 ,  A61K31/513 ,  C12Q1/68 ,  C07H21/04

    CPC classification number: C12N15/1137 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12Y102/01002 ,  C12Y201/01045 ,  C12N2310/3525

    Abstract: The present invention provides antisense oligonucleotides useful for identifying drug targets for cancer therapies and for enhancing current cancer therapies. The oligonucleotides of the invention are complementary to thymidylate synthase mRNA and affect expression of at least one other gene. For the enhancement of cancer therapies, such antisense oligonucleotides can be used in conjunction with standard chemotherapeutic agents in order to target thymidylate synthase, as well as other appropriate targets. The antisense oligonucleotides and the methods of the invention constitute improved antisense therapies with application to a variety of cancers.

    Abstract translation: 本发明提供了用于鉴定癌症疗法的药物靶标和用于增强目前的癌症疗法的反义寡核苷酸。 本发明的寡核苷酸与胸苷酸合酶mRNA互补并影响至少一种其他基因的表达。 为了增强癌症疗法，这种反义寡核苷酸可以与标准化学治疗剂结合使用，以靶向胸苷酸合酶以及其他合适的靶标。 反义寡核苷酸和本发明的方法构成了应用于多种癌症的改进的反义治疗。

    SRM Assay to Indicate Cancer Therapy
    7.
    发明申请
    SRM Assay to Indicate Cancer Therapy 审中-公开

    公开(公告)号：US20180195107A1

    公开(公告)日：2018-07-12

    申请号：US15837888

    申请日：2017-12-11

    Applicant: EXPRESSION PATHOLOGY, INC.

    Inventor： David B. KRIZMAN ,  Todd HEMBROUGH ,  Sheeno THYPARAMBIL ,  Wei-Li LIAO

    IPC: C12Q1/37 ,  G01N33/574 ,  C12N9/10 ,  C12N9/12 ,  C07K16/40 ,  G01N33/68

    CPC classification number: C12Q1/37 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/1007 ,  C12N9/12 ,  C12Y201/01045 ,  C12Y207/10001 ,  G01N33/57484 ,  G01N33/6848 ,  G01N2560/00 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue™ reagents and protocol and the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry, by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an ALK, Ros, Ron, Ret, TS, and/or FGFR1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

Patent Agency Ranking